Compare HCWB & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCWB | MLEC |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 4.9M |
| IPO Year | 2021 | N/A |
| Metric | HCWB | MLEC |
|---|---|---|
| Price | $1.61 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 141.6K | 131.8K |
| Earning Date | 11-14-2025 | 01-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,026.00 | N/A |
| Revenue This Year | $178.64 | $20.42 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 170.36 |
| 52 Week Low | $1.84 | $0.39 |
| 52 Week High | $41.20 | $8.00 |
| Indicator | HCWB | MLEC |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 36.36 |
| Support Level | $1.89 | $0.41 |
| Resistance Level | $2.15 | $0.48 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 2.94 | 24.66 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.